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Abstract
Objective The objective of this study was to study the associ-
ation between antithrombotic treatment and risk of hemor-
rhagic stroke (HS) in patients with atrial fibrillation (AF) treat-
ed in primary health care.
Methods Study population included all adults (n = 12,215)
45 years and older diagnosed with AF at 75 primary care
centers in Sweden 2001–2007. Outcome was defined as a first
hospital episode with a discharge episode of HS after the AF
diagnosis. Association between HS and persistent treatment
with antithrombotic agents (warfarin, acetylsalicylic acid
(ASA), clopidogrel) was explored using Cox regression anal-
ysis, with hazard ratios (HRs) and 95 % CIs. Adjustment was
made for age, socioeconomic status, and co-morbid cardiovas-
cular conditions.
Results During amean of 5.8 years (SD 2.4) of follow-up, 162
patients (1.3 %; 67 women and 95 men) with HS were record-
ed. The adjusted risk associated with persistent warfarin treat-
ment compared to no antithrombotic treatment consistently
showed no increased HS risk, HR for women 0.53 (95 % CI
0.23–1.27) and for men 0.55 (95 % CI 0.29–1.04); corre-
sponding HRs for ASA were, for women, 0.45 (95 % CI
0.14–1.44) and, for men, 0.56 (95 % CI 0.24–1.29).
Conclusions In this clinical setting, we found no evidence
pointing to an increased risk of HS with antithrombotic
treatment.
Key messages 1. The adjusted risk associated with persistent warfarin
treatment compared to no antithrombotic treatment showed no increased
risk of hemorrhagic stroke.
2. Furthermore, the adjusted risk associated with persistent ASA
treatment showed the same pattern.
3. The main take-home message is that in this highly selected group of
patients, prescription of warfarin therapy in a country with an excellent
track record of warfarin management does not seem to result in an ex-
aggerated increased risk of hemorrhagic stroke.
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Introduction
Atrial fibrillation (AF) is the most common heart rhythm
disorder in the world [1], affecting around 2 % of the
Swedish population [2]. The most important complication
in patients with AF is the risk of ischemic stroke, estimat-
ed to be five times as common as in individuals without
AF [3], with a higher risk among women [4].
Anticoagulant treatment plays a significant role in
preventing stroke in AF patients, and anticoagulant (ear-
lier predominantly warfarin) therapy has definite benefits
over antiplatelet (mostly acetylsalicylic acid (ASA)) ther-
apy [5]. Given the possible debilitating consequences of
stroke and considering the good preventive effect of anti-
coagulant treatment, it is of great importance to identify
individuals with increased risk of stroke among AF pa-
tients. Besides, the risk of bleeding complications is a
main concern, especially the risk of hemorrhagic stroke
(HS) [6]. In general, among stroke patients, 10–20 % have
intracerebral bleedings, with a higher risk of functional
disability and mortality than ischemic strokes [7].
Among f a c t o r s o f impo r t a n c e o f po t e n t i a l
anticoagulant-associated hemorrhages are increasing age,
prior ischemic stroke, hypertension, and antiplatelet use in
addition to anticoagulation [8]. However, in clinical prac-
tice complications of warfarin treatment, in general, seem
low [9], and the organization of anticoagulation treatment
in Sweden, often performed in primary care, seems to
contribute to this [10].
The objective of the present study was to explore the
risk of first hemorrhagic stroke in men and women in
relation to prescription of antithrombotic drugs in a large
cohort of AF patients treated in primary health care. We




This study was performed using individual-level patient
data from 75 Swedish primary health care centers
(PHCCs), mostly located in Stockholm County (n = 48).
Men and women with a registered AF diagnosis visiting
any of the participating PHCCs between 2001 and 2007
were included in the study. The EPR files of the patients
were linked to a database constructed using Swedish na-
tional registers (for more information, see Supplementary
files). This research database included individual clinical
patient data from a total of 1,098,420 subjects registered
at these 75 PHCCs. A follow-up was performed using the
Swedish Cause of Death Register, which has been shown
to be almost complete, 99.8 % [11].
Study population and co-morbidities
The study included all patients with diagnosed AF, iden-
tified by the presence of the ICD-10 code (tenth version
of the WHO’s International Classification of Diseases) for
atrial fibrillation (I48) in the patients’ medical records.
The following cardiovascular-related disorders were used
as covariates (see also Supplementary files): hypertension,
coronary heart disease (CHD), congestive heart failure
(CHF), cerebrovascular diseases (CVDs), and diabetes
mellitus. Patients with a first HS during the period were
identified, and patients with a first HS before the first AF
diagnosis were excluded. In total, 6600 men and 5615
women aged 45 years or older at the time of AF diagnosis
and who visited any of the 75 participating PHCCs from
January 1, 2001, until December 31, 2007, and with data
on neighborhood socioeconomic status were included in
the study.
Outcome variable
The time to first hemorrhagic stroke episode during the as-
sessment period (from registration of first AF diagnosis during
2001–2007 until end of follow-up, December 31, 2010) was
defined as having an ICD-10 code (I60–I61) in the Inpatient
Register (hospital admissions) or the Cause of Death Register.
Time to mortality from first AF diagnosis to death was
registered (until December 31, 2010).
Demographic and socioeconomic variables
Sex: men and women.
Age was categorized as follows: 45–54, 55–64, 65–74, 75–
84, and ≥85 years.
The neighborhood socioeconomic status (SES) areas were
categorized into three groups according the neighborhood in-
dex: more than one standard deviation (SD) below the mean
(high SES or low deprivation level), more than one SD above
the mean (low SES or high deprivation level), and within one
SD of the mean (middle SES or deprivation level; for more
information, see Supplementary files).
Educational attainment was categorized as ≤9 years (partial
or complete compulsory schooling), 10–12 years (partial or
complete secondary schooling), and >12 years (attendance at
college and/or university).
Marital status was characterized as married, unmarried, di-
vorced, or widowed.
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Risk classification of stroke
The stroke risk can be evaluated based on CHADS2 or
CHA2DS2-VASc [12].
Anticoagulant treatment
Prescriptions of antithrombotic treatment, i.e., both anti-
coagulants and thrombocyte aggregation inhibitors, from
2001 to 2007, were obtained from patient records in pri-
mary health care. We studied prescription of warfarin
(B01AA03) , ASA (B01AC06 , B01AC30) , and
clopidogrel (B01AC04) or ticlopidine (B01AC05).
Ticlopidine was categorized in the clopidogrel group.
The prescribed antithrombotic drugs were classified as
Bintention-to-treat^ (ITT) if ever present before the years
of the first HS or if present at any time among subjects
not experiencing a HS [13]. The prescribed warfarin was
classified as Bper protocol^ (PP) if prescribed in the year
of the first HS or prescribed among subjects not
experiencing a HS at least during half of the years after
the first recorded diagnosis of AF or during both 2006
and 2007, presuming a consistent treatment (as no pre-
scription data after 2007 were available).
Statistical analysis
Baseline characteristics for all included men and women, as
well as for those with a recorded first hemorrhagic stroke,
were presented as mean (SD) if continuous and as frequencies
if categorical.
We classified subjects without and with a first HS ac-
cording to their CHADS2 and CHA2DS2-VASc scores.
We also made stratified analyses in subjects classified as
not having a per protocol prescription of warfarin.
We also estimated the incidence rates of a first HS per
100 person-years at risk for men and women. The relative
risk of HS for patients on ITT and PP warfarin treatment
was analyzed using Cox proportional hazard regression
analysis and presented as hazard ratios (HRs) with 95 %
confidence intervals (CIs), with the following three
models: model 1 age adjusted, model 2 also including
socioeconomic factors (educational level, marital status,
and neighborhood SES), and model 3 also including car-
diovascular co-morbidity. Model specification was tested,
and models were checked for interactions. Cox regression
was used to estimate mortality risk in patients with an HS,
with patients without an HS as referents, with HRs and
95 % CIs.
The study was approved by the regional ethics boards at
Karolinska Institutet and Lund University.
Results
The characteristics of men and women with AF treated in
primary care (all, n = 12,215) without and with a first
recorded HS are shown in Table 1 (data divided by age
and by persistent antithrombotic treatment or not in
Supplementary Tables 1 and 2, respectively). Mean time
to follow-up was 5.77 years (SD 2.41), median follow-up
was 5.50 years, and a total of 70,426 person-years at risk
were analyzed, i.e., 31,966 among women and 38,460
among men. In total, 162 patients (1.3 %) with HS were
recorded, with 67 women (1.2 %) and 95 men (1.4 %).
Out of the 67 women with a hemorrhagic stroke, 21
(31 %) were treated with warfarin only, 14 (21 %) were
treated with ASA only, 2 (3 %) were treated with a com-
bination of warfarin and ASA, none was treated with
clopidogrel, and 30 (45 %) had no antithrombotic treat-
ment at all. Among the 95 men, 34 (36 %) were treated
with warfarin only, 17 (18 %) were treated with ASA
only, 8 (8 %) were treated with a combination of warfarin
and ASA, 1 (1 %) was treated with clopidogrel only, and
35 (37 %) had no antithrombotic treatment at all. No
statistically significant increased risk for patients treated
with any antithrombotic drug or combination of drugs was
found. A recorded HS was present among 37 women
(1.0 %) on persistent (per protocol) antithrombotic treat-
ment vs 30 (1.5 %) among women without persistent
treatment, with corresponding numbers among men of
60 (1.4 %) and 35 (1.6 %), respectively (division by
s c o r e s o n CHADS 2 a n d CHA 2DS 2 -VAS c i n
Supplementary Tables 3 and 4).
Incident rates for a hemorrhagic stroke per 100 person-
years at risk are shown in Table 2, with lower estimates
for women than for men, 0.21 vs. 0.25. The age-adjusted
relative risk of a hemorrhagic stroke for women as com-
pared to men was HR 0.75 (95 % CI 0.54–1.03). Incident
rates were also calculated in subjects without PP anti-
thrombotic treatment, for women 0.28 (95 % CI 0.19–
0.40) and for men 0.28 (95 % CI 0.20–0.40) cases per
100 person-years.
The risks of a first hemorrhagic stroke with PP treatment
with warfarin are shown in men and women in Table 2, with
non-significant estimates in fully adjusted models. Among
subjects below 65 years of age (women and men combined),
we found fully adjusted HRs for PP warfarin, PPASA, and all
PP antithrombotic treatment vs patients without any PP treat-
ment at all of 1.04 (95 % CI 0.79–1.38), 1.63 (95 % CI 0.44–
6.04), and 1.14 (95 % CI 0.41–3.14), respectively. The corre-
sponding fully adjusted HRs for subjects 65 years and above
were 0.45 (95 % CI 0.26–0.81), 0.35 (95 % CI 0.16–0.78),
and 0.45 (95 % CI 0.28–0.75).
When patients with and without persistent antithrombotic
treatment were compared, the mean age among women was
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slightly lower (76.9 vs. 77.5 years) but among men was slight-
ly higher (72.6 vs. 71.2 year) (Supplementary Table 3). For
both women and men, patients with persistent antithrombotic
treatment vs patients without this were more likely to have
hypertension, CHD and diabetes.
The mortality risk for men and women with a first hemor-
rhagic stroke compared to their counterparts without this was
estimated (Table 3), with incidence rates per 100 person-years
at risk and HRs by Cox regression. There was a significantly
higher risk of mortality in both men and women.
Table 1 Data on women
(n = 5615) and men (n = 6600)
aged 45+ years with a diagnosis
of atrial fibrillation and without
(n = 12,121) or with (n = 162) a
hemorrhagic stroke (HS) in
primary care from January 1,
2001, to December 31, 2007
Women Men
Without HS With HS Without HS With HS
n = 5548 n = 67 p value n = 6505 n = 95 p value
Age (years), mean (SD) 77.1 (9.3) 77.3 (7.2) 0.80 72.1 (10.2) 75.2 (9.0) 0.0032
Age group (years) 0.28 0.067
n (%) n (%) n (%) n (%)
45–54 104 (1.9) 0 (0.0) 368 (5.7) 1 (1.1)
55–64 516 (9.3) 4 (6.0) 1205 (18.5) 12 (12.6)
65–74 1246 (22.5) 16 (23.9) 1994 (30.7) 32 (33.7)
75–84 2488 (44.8) 37 (55.2) 2287 (35.2) 35 (36.8)
85+ 1194 (21.5) 10 (14.9) 651 (10.0) 15 (15.8)
Neighborhood SES 0.13 0.25
High 1921 (34.6) 16 (23.9) 2597 (39.9) 41 (43.2)
Middle 2734 (49.3) 36 (53.7) 2966 (45.6) 46 (48.4)
Low 893 (16.1) 15 (22.4) 942 (14.5) 8 (8.4)
Marital status 0.41 0.40
Married 1643 (29.8) 14 (20.9) 3865 (59.7) 62 (65.3)
Unmarried 391 (7.1) 6 (9.0) 617 (9.5) 8 (8.4)
Divorced 780 (14.1) 12 (17.9) 1002 (15.5) 9 (9.5)
Widowed 2708 (49.0) 35 (52.2) 996 (15.4) 16 (16.8)
Educational level 0.48 0.58
Compulsory school 2561 (52.6) 29 (48.3) 2433 (39.5) 34 (39.5)
Secondary school 1598 (32.8) 24 (40.0) 2318 (37.6) 36 (41.9)
College/university 712 (14.6) 7 (11.7) 1410 (22.9) 16 (18.6)
AF-related disease
Hypertension 2706 (48.8) 39 (58.2) 0.13 2694 (41.4) 39 (41.1) 0.58
CHD 1156 (20.8) 15 (22.4) 0.76 1314 (20.2) 18 (19.0) 0.76
Heart failure 1140 (20.6) 8 (11.9) 0.082 1127 (17.3) 22 (23.2) 0.14
Valvular disease 272 (4.9) 4 (6.0) 0.57 288 (4.4) 3 (3.2) 0.80
Diabetes mellitus 1076 (19.4) 12 (17.9) 0.76 1284 (19.7) 16 (16.8) 0.48
Drugs
Ever warfarin 2651 (47.8) 38 (56.7) 0.15 3651 (56.1) 57 (60.0) 0.45
Warfarin ITT 2568 (46.3) 38 (56.7) 0.089 3541 (54.4) 57 (60.0) 0.28
Warfarin PP 2015 (36.3) 23 (34.3) 0.74 2763 (42.5) 42 (44.2) 0.73
Ever ASA 3242 (58.4) 36 (53.7) 0.44 3416 (52.5) 53 (55.8) 0.53
ASA ITT 2863 (51.6) 31 (46.3) 0.39 3007 (46.2) 45 (47.4) 0.83
ASA PP 1780 (32.1) 16 (23.9) 0.15 1924 (29.6) 25 (26.3) 0.49
Ever clopidogrel 195 (3.5) 0 0.17 202 (3.1) 3 (3.2) 0.77
Clopidogrel ITT 141 (2.5) 0 0.42 159 (2.4) 3 (3.2) 0.51
Clopidogrel PP 61 (1.1) 0 1.0 61 (0.9) 1 (1.1) 0.60
Prescription of antithrombotic drugwas classified as Bintention to treat^ (ITT) if ever present before the year of the
first stroke or present among subjects not experiencing a stroke and classified as Bper protocol^ (PP) if present the
year before and the year of first stroke or present among subjects not experiencing a stroke if present at least during
3 years, of at least 50 % of actual years after the first recorded year of AF or during both 2006 and 2007
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Discussion
The main findings of this study were that antithrombotic
treatment was not significantly associated with an in-
creased risk of hemorrhagic stroke. Yet, a higher mortality
risk among patients that suffered from a hemorrhagic
stroke was seen and was especially high among women.
Our findings pointing to a lower risk of HS with anti-
coagulant treatment were unexpected and quite remark-
able. One possible explanation to the unexpected findings
could be the misclassification of diagnoses, e.g., that is-
chemic strokes were classified as hemorrhagic strokes. An
initially presented ischemic stroke could have a bleeding
component and thus being classified as a bleeding stroke.
Another possible explanation could be confounding by
indication, i.e., patients regarded as having a higher bleed-
ing risk could be withdrawn from anticoagulant treatment.
Besides, we cannot exclude the presence of residual con-
founding, and the data being used could be of suboptimal
accuracy, with possible misclassification of treatment.
In an earlier national Swedish study, the rates of HS
were equal in patients treated with warfarin, ASA, or
without prophylaxis [14]. Furthermore, another Swedish
study found that patients with some contraindication to
anticoagulant treatment (dementia, alcohol abuse, renal
disease, anemia, any severe bleeding, or frequent falls)
but still on warfarin or ASA treatment had a 2–3-fold
increased bleeding risk vs patients without contraindica-
tions, and the authors of that study concluded that
Bwarfarin-treated patients are highly selected and that de-
cisions not to treat elderly, frail high-risk patients often
may be related to complicating co-morbidities and a poor
prognosis^ [15]. The lower risk estimates for older pa-
tients with higher rates of contraindications suggest that
these patients are more carefully selected for anticoagu-
lant and antithrombotic treatment, in line with an earlier
study [15]. Thus, the clinical decision not to treat frail
patients could explain the low risk estimates for HS with
antithrombotic treatment.
We confirmed a higher rate of HS among men than in
women with AF that has been reported in previous studies
[14, 16]. We also confirmed a higher mortality risk among
both men and women after hemorrhagic stroke in AF than
in those with AF without hemorrhagic stroke [7]. Yet, as
far as we know, the present study is the first to show an
increased mortality risk of HS among patients with AF
treated in primary care.
There are certain limitations of this study. The number
of hemorrhagic stroke events was low, and the study may
have been underpowered to show an increased risk of
anticoagulant treatment. This is an observational study,
and prescription of antithrombotic drugs, especially of
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those we recorded, i.e., confounding by indication may be
one explanation to our results [17]. We did not include
subarachnoid hemorrhage [18], which contributes to
around 3 % of stroke [19]. Our data were extracted from
electronic patient records in primary health care, and data
may have been incomplete, e.g., for listings of diagnoses,
even if we could expect the diagnoses of cardiovascular
diseases and diabetes to be more accurate and complete
than many other diagnoses. In contrast, we used hospital
data for the diagnosis of the main outcome. In general, the
validity of data from hospital registers has been found to
be high [20], even if stroke diagnoses seem to be less
valid [18, 21]. Besides, severe hemorrhagic strokes could
present as sudden death. We had no data available on the
type of atrial fibrillation (paroxysmal, persistent, perma-
nent) and rhythm (sinus rhythm, fibrillation). We had no
data on some clinical parameters of patients with AF such
as electroconversion of AF, catheter ablation, or Cox-
Maze operations. Additionally, the HAS-BLED score
was not possible to calculate as we had no data on renal
or liver function; bleeding history or predisposition, in
general; international normalized ratio; or intake of drugs
or alcohol [22]. Besides, we did not have access to plate-
let count and renal function, which are also important
predictors of bleeding. Furthermore, we had no data on
the non-vitamin K antagonist oral anticoagulant (NOAC)
treatments. However, since the variables available in the
present study were obtained from primary health care
electronic patient records, they may be assumed to mirror
the information available for the clinician. As we did not
have access to data on time in therapeutic INR range
(TIR), we used analyses of PP treatment as attempts in
trying to reflect a regular warfarin treatment, and analyses
of ITT or not reflect a more crude division. In the statis-
tical analyses, it was not possible to find a balanced mod-
el when trying to use propensity score analysis.
Despite the limitations, one of the key strengths of this
study is the linkage of clinical data from individual pa-
tients to national demographic and socioeconomic data
with less than 1 % missing data. The clinical data were
also highly complete, and studies using hospital patients
only may underestimate the co-morbidity [2]. Another
strength is the sample size of the study, i.e., 6600 men
and 5615 women and 70,000 person-years at risk
analyzed.
In conclusion, our results suggest that anticoagulant
and other antithrombotic treatment is safe in clinical prac-
tice in primary care with no increased risk of hemorrhagic
strokes, suggesting that GPs in Swedish primary care are
effective in excluding frail patients at higher risk of bleed-
ings from antithrombotic treatment. Besides, in an earlier
study, we found the preventive effect by both warfarin
and ASA on ischemic stroke in primary care to be high
[13]. The main take-home message is that in this highly
selected group of patients, the benefits and risk of warfa-
rin therapy in a country with an excellent track record of
warfarin management could be satisfactorily balanced.
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Table 3 Risk of mortality among women and men with atrial fibrillation and with or without a hemorrhagic stroke (HS)
Events/at risk (n) Incidence rate (95 % CI) Mortality risk by Cox regression (95 % CI)
Model 1 Model 2 Model 3
Women
With HS 40/67 11.31 (8.29–15.41) 1.88 (1.37–2.57) 2.12 (1.51–2.98) 2.25 (1.60–3.16)
Without HS 1923/5548 6.01 (5.75–6.29) 1 (ref) 1 (ref) 1 (ref)
Men
With HS 48/95 8.82 (6.64–11.70) 1.47 (1.11–1.96) 1.50 (1.10–2.06) 1.46 (1.07–2.01)
Without HS 1935/6505 5.00 (4.78–5.23) 1 (ref) 1 (ref) 1 (ref)
Incidence rate per 100 person-years at risk. Cox regression for mortality risk in women andmenwith HS.Model 1 age adjusted,model 2 also adjusted for
socioeconomic factors (neighborhood socioeconomic status, educational level, and marital status), and model 3 also adjusted for cardiovascular co-
morbidity (for women including interaction term between age and CHD)
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